Compare SMX Security Matters plc (SMX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs Vertex Pharmaceuticals Incorporated — how do they compare? SMX Security Matters plc trades at $3.79 (market cap $4.13M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 30883.8× SMX Security Matters plc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SMX Security Matters plc for 21 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SMX | VRTX | |
|---|---|---|
Market Cap | $4.13M | $127.55B |
Volume | 124,362 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $74.08K | $557.96 |
52-Week Low | $3.79 | $407.37 |
Typical Hold Time | 21 Days | 120 Days |
Enterprise Value | -$27.20M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX trades at $3.90, up 2.9% today, but faces significant financial challenges with no revenue reported for 2025 and a net loss of $169.18 million. The stock shows bearish technical signals with moving averages indicating selling pressure, though oscillators suggest potential short-term momentum. Recent news highlights the company's focus on recycled plastic verification technology and growing media coverage from major outlets.
The outlook remains highly speculative given the absence of revenue and substantial losses. Investment opportunity hinges on successful commercialization of SMX's material verification platform, while risks include cash burn sustainability and intense competition in the circular economy space. Wall Street sentiment appears cautious due to the company's unproven business model.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
